Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status
To better understand your feelings and expectations about immunotherapy
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 6, 2024 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- M.D. Anderson Cancer Center
- Interventions being studied
- Behavioral: Questionnaires; Behavioral: Interview
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Patients being considered for or within 2 months of starting immunotherapy for advanced cancer 2. Patient ≥18 years of age 3. ECOG ≥2 4. Cognitively able to understand consent and complete questionnaire as determined by the interviewer at the time of study enrollment 5. English speaking 6. Willing to participate in the study and sign informed consent 7. The study will include medical oncologists that treat advanced cancers
1. Treatment for curative intent 2. Presence of Delirium (as determined by score \>13 on MDAS 46, appendix A)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- M D Anderson Cancer CenterHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 6, 2024. Always confirm current availability with the study team.